[go: up one dir, main page]

UY30365A1 - Comprimido bicapa para la prevención de los accidentes cardiovasculares - Google Patents

Comprimido bicapa para la prevención de los accidentes cardiovasculares

Info

Publication number
UY30365A1
UY30365A1 UY30365A UY30365A UY30365A1 UY 30365 A1 UY30365 A1 UY 30365A1 UY 30365 A UY30365 A UY 30365A UY 30365 A UY30365 A UY 30365A UY 30365 A1 UY30365 A1 UY 30365A1
Authority
UY
Uruguay
Prior art keywords
prevention
pharmaceutically acceptable
bicapa
compressed
cardiovascular accidents
Prior art date
Application number
UY30365A
Other languages
English (en)
Inventor
Marta Guerrero
Anna Orriols Reig
Guglietta Antonio
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38556680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30365(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of UY30365A1 publication Critical patent/UY30365A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención comprende un comprimido bicapa que a su vez comprende un compartimiento que contiene como ingrediente activo un compuesto de simvastatina farmacéuticamente aceptable; y otro compartimiento separado de aquél que contiene como ingredientes activos un compuesto de lisinopril farmacéuticamente aceptable y un compuesto de ácido fólico farmacéuticamente aceptable, para la prevención de los accidentes cardiovasculares en condiciones o enfermedades de alto riesgo.
UY30365A 2006-05-24 2007-05-24 Comprimido bicapa para la prevención de los accidentes cardiovasculares UY30365A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200601355A ES2300188B1 (es) 2006-05-24 2006-05-24 Comprimido bicapa para la prevencion de los accidentes cardiovasculares.

Publications (1)

Publication Number Publication Date
UY30365A1 true UY30365A1 (es) 2007-08-31

Family

ID=38556680

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30365A UY30365A1 (es) 2006-05-24 2007-05-24 Comprimido bicapa para la prevención de los accidentes cardiovasculares

Country Status (23)

Country Link
US (1) US20090196922A1 (es)
EP (1) EP2026769B1 (es)
JP (1) JP2009537583A (es)
KR (1) KR20090020577A (es)
CN (1) CN101453992A (es)
AR (1) AR061047A1 (es)
AT (1) ATE460924T1 (es)
AU (1) AU2007253580B2 (es)
BR (1) BRPI0712267A2 (es)
CA (1) CA2652838A1 (es)
CY (1) CY1110097T1 (es)
DE (1) DE602007005372D1 (es)
DK (1) DK2026769T3 (es)
ES (2) ES2300188B1 (es)
MX (1) MX2008014782A (es)
NO (1) NO20084998L (es)
PL (1) PL2026769T3 (es)
PT (1) PT2026769E (es)
RU (1) RU2445088C2 (es)
SI (1) SI2026769T1 (es)
TW (1) TW200812647A (es)
UY (1) UY30365A1 (es)
WO (1) WO2007134870A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101633939B1 (ko) * 2007-10-10 2016-06-27 아반토르 퍼포먼스 머티리얼스, 인크. 직접 압축성 고기능성 과립 미세결정 셀룰로스계 부형제, 그의 제조 방법 및 용도
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
BR112012011726A2 (pt) * 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
EP2523657A1 (en) * 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
WO2014059512A1 (en) * 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
WO2014152296A1 (en) 2013-03-15 2014-09-25 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
CA2953396C (en) 2014-07-03 2022-11-08 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
EA201890160A1 (ru) * 2015-06-26 2018-06-29 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
KR102824158B1 (ko) * 2015-07-17 2025-06-25 애브비 인코포레이티드 Hcv의 치료를 위한 고형 약제학적 조성물
IL270152B2 (en) * 2017-04-25 2024-10-01 Proteus Digital Health Inc Lisinopril compositions with an ingestible event marker
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
WO2001076632A1 (en) * 2000-04-10 2001-10-18 Wald Nicholas J Formulation for the prevention of cardiovascular disease
US6462174B1 (en) * 2001-06-25 2002-10-08 Astrazeneca Ab Amorphous compound
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
DE60303378T2 (de) * 2002-02-05 2006-11-02 Ricoh Company, Ltd. Tinte für den tintenstrahldruck, tintenkombination, tintenpatrone, tintenstrahldrucker sowie tintenstrahldruckverfahren
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
BRPI0412557A (pt) * 2003-07-28 2006-09-19 Reddys Lab Inc Dr forma de dosagem farmacêutica de eventos cardiovasculares
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets

Also Published As

Publication number Publication date
PT2026769E (pt) 2010-06-11
DK2026769T3 (da) 2010-07-19
ES2300188B1 (es) 2009-05-01
RU2008151105A (ru) 2010-06-27
AU2007253580B2 (en) 2012-03-22
WO2007134870A1 (en) 2007-11-29
ATE460924T1 (de) 2010-04-15
US20090196922A1 (en) 2009-08-06
MX2008014782A (es) 2008-11-28
CY1110097T1 (el) 2015-01-14
HK1129577A1 (en) 2009-12-04
AU2007253580A1 (en) 2007-11-29
CN101453992A (zh) 2009-06-10
CA2652838A1 (en) 2007-11-29
KR20090020577A (ko) 2009-02-26
JP2009537583A (ja) 2009-10-29
PL2026769T3 (pl) 2010-09-30
AR061047A1 (es) 2008-07-30
TW200812647A (en) 2008-03-16
RU2445088C2 (ru) 2012-03-20
DE602007005372D1 (de) 2010-04-29
BRPI0712267A2 (pt) 2012-01-17
EP2026769A1 (en) 2009-02-25
SI2026769T1 (sl) 2010-08-31
ES2300188A1 (es) 2008-06-01
NO20084998L (no) 2009-02-23
ES2342905T3 (es) 2010-07-16
EP2026769B1 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
UY30365A1 (es) Comprimido bicapa para la prevención de los accidentes cardiovasculares
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
DOP2011000229A (es) Composicion farmaceutica solida que comprende amlodipina y losartan
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
CL2014002325A1 (es) Composicion farmaceutica que comprende metformina y un inhibidor de dpp-4 con preferencia linagliptina o un inhibidor de sglt-2 con preferencia 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno; y comprimido de administracion oral.
MX2009010289A (es) Composiciones para administracion nasal.
CO6400186A2 (es) Tabletas de acetato de ulipristal
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
WO2009134086A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2012106665A3 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
MX2010007083A (es) Combinacion anti-retroviral.
AR071094A1 (es) Capsula para la prevencion de enfermedades cardiovasculares y su uso
WO2007041368A3 (en) Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
MX356245B (es) Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un gabapentinoide.
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2007035816A3 (en) Paroxetine compositions